High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

(2020) Alessio Cortellini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

(2020) Luca Cantini et al.   Frontiers in Oncology

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program

(2020) Luca Cantini et al.   Translational Lung Cancer Research

Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

(2019) K M Heinhuis et al.   ANNALS OF ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins

(2018) Federica Iannelli et al.   Recent Patents on Anti-Cancer Drug Discovery

The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery

(2018) Yun Xia et al.   CELL

Strategies for designing synthetic immune agonists

(2016) Tom Y.-H. Wu   IMMUNOLOGY

Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates

(2013) Naomi Gronich et al.   Nature Reviews Clinical Oncology